ARQT insider filings
Arcutis Biotherapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen ARQT transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 15 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 10 filings by 5 insiders — 113,660 shares, $3,281,738 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
- Largest priced transaction: sale of 40,000 shares @ $34.32 ($1,372,672) by Matsuda Masaru, filed 2026-11-04.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Matsuda Masaru — EVP, Chief Legal Officer | 3 | — | 4 legs · 54,882 sh · $1,753,353 | 2 |
| Curran Terrie — Director | 2 | — | 3 legs · 39,272 sh · $984,035 | 6 |
| Welgus Howard G. — Director | 3 | — | 3 legs · 14,186 sh · $374,837 | 18 |
| Watanabe Todd — See Remarks, Director | 2 | — | 1 leg · 4,377 sh · $139,466 | 1 |
| Burnett Patrick — EVP, Chief Medical Officer | 1 | — | 1 leg · 943 sh · $30,047 | — |
| SCOTT ROBERT A — Director | 3 | — | — | 3 |
| Lisicki Robert — EVP, Chief Commercial Officer | 1 | — | — | — |
Recent insider filings — Arcutis Biotherapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Welgus Howard G. — Director | Option exercise (M): 822 @ $6.52 · Option exercise (M): 1,018 @ $7.51 · Option exercise (M): 2,254 @ $8.63 · Sale (S): 4,728 @ $28.16 · Option exercise (M): 822 (derivative) @ $0 · Option exercise (M): 1,018 (derivative) @ $0 · +1 more | EDGAR |
| 2026-11-17 | 4 | Watanabe Todd — See Remarks, Director | Gift (G): 144,232 @ $0 | EDGAR |
| 2026-11-04 | 3/A | SCOTT ROBERT A — Director | Holdings only — no transactions reported | EDGAR |
| 2026-11-04 | 3 | Lisicki Robert — EVP, Chief Commercial Officer | Holdings only — no transactions reported | EDGAR |
| 2026-11-04 | 4 | Watanabe Todd — See Remarks, Director | Sale (S): 4,377 @ $31.86 | EDGAR |
| 2026-11-04 | 4 | Burnett Patrick — EVP, Chief Medical Officer | Sale (S): 943 @ $31.86 | EDGAR |
| 2026-11-04 | 4 | Matsuda Masaru — EVP, Chief Legal Officer | Sale (S): 1,219 @ $31.86 · Option exercise (M): 40,000 @ $3.64 · Sale (S): 40,000 @ $34.32 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2026-10-28 | 3 | SCOTT ROBERT A — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-28 | 4 | SCOTT ROBERT A — Director | Grant/award (A): 2,819 @ $0 · Grant/award (A): 20,507 (derivative) @ $0 · Grant/award (A): 8,663 (derivative) @ $0 | EDGAR |
| 2026-10-19 | 4 | Welgus Howard G. — Director | Option exercise (M): 822 @ $6.52 · Option exercise (M): 1,018 @ $7.51 · Option exercise (M): 2,254 @ $8.63 · Sale (S): 4,728 @ $26.93 · Option exercise (M): 822 (derivative) @ $0 · Option exercise (M): 1,018 (derivative) @ $0 · +1 more | EDGAR |
| 2026-09-18 | 4 | Matsuda Masaru — See Remarks | Sale (S): 3,674 @ $25.00 | EDGAR |
| 2026-09-17 | 4 | Welgus Howard G. — Director | Option exercise (M): 822 @ $6.52 · Option exercise (M): 1,019 @ $7.51 · Option exercise (M): 2,255 @ $8.63 · Sale (S): 4,730 @ $24.18 · Option exercise (M): 822 (derivative) @ $0 · Option exercise (M): 1,019 (derivative) @ $0 · +1 more | EDGAR |
| 2026-09-10 | 4 | Matsuda Masaru — See Remarks | Sale (S): 9,989 @ $25.03 | EDGAR |
| 2026-08-28 | 4 | Curran Terrie — Director | Option exercise (M): 11,148 @ $7.51 · Sale (S): 11,148 @ $25.03 · Option exercise (M): 27,052 @ $8.63 · Sale (S): 27,052 @ $25.03 · Option exercise (M): 11,148 (derivative) @ $0 · Option exercise (M): 27,052 (derivative) @ $0 | EDGAR |
| 2026-08-24 | 4 | Curran Terrie — Director | Option exercise (M): 1,072 @ $7.51 · Sale (S): 1,072 @ $26.04 · Option exercise (M): 1,072 (derivative) @ $0 | EDGAR |
| 2026-08-21 | 4 | Burnett Patrick — See Remarks | Sale (S): 1,697 @ $27 | EDGAR |
| 2026-08-19 | 4 | Welgus Howard G. — Director | Option exercise (M): 822 @ $6.52 · Option exercise (M): 1,019 @ $7.51 · Option exercise (M): 2,255 @ $8.63 · Sale (S): 4,730 @ $26.18 · Option exercise (M): 822 (derivative) @ $0 · Option exercise (M): 1,019 (derivative) @ $0 · +1 more | EDGAR |
| 2026-08-13 | 4 | Burnett Patrick — See Remarks | Option exercise (M): 8,300 @ $3.64 · Sale (S): 8,300 @ $26.52 · Option exercise (M): 6,700 @ $3.64 · Sale (S): 6,700 @ $26.08 · Option exercise (M): 8,300 (derivative) @ $0 · Option exercise (M): 6,700 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Watanabe Todd — See Remarks, Director | Sale (S): 4,375 @ $26.12 | EDGAR |
| 2026-08-05 | 4 | Matsuda Masaru — See Remarks | Sale (S): 1,230 @ $26.12 | EDGAR |
| 2026-08-05 | 4 | Burnett Patrick — See Remarks | Sale (S): 955 @ $26.12 | EDGAR |
| 2026-07-17 | 4 | Welgus Howard G. — Director | Option exercise (M): 822 @ $6.52 · Option exercise (M): 1,019 @ $7.51 · Option exercise (M): 2,255 @ $8.63 · Sale (S): 4,730 @ $26.91 · Option exercise (M): 822 (derivative) @ $0 · Option exercise (M): 1,019 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-17 | 4 | Peetz Christopher — Director | Grant/award (A): 4,315 @ $0 · Grant/award (A): 21,486 (derivative) @ $0 · Grant/award (A): 13,010 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | LIN SUE-JEAN — Director | Sale (S): 4,946 @ $24.38 | EDGAR |
| 2026-06-17 | 4 | Welgus Howard G. — Director | Option exercise (M): 822 @ $6.52 · Option exercise (M): 1,019 @ $7.51 · Option exercise (M): 2,255 @ $8.63 · Sale (S): 4,096 @ $24.41 · Sale (S): 635 @ $25.67 · Option exercise (M): 822 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-12 | 4/A | Heron Patrick J — Director | Holdings only — no transactions reported | EDGAR |
| 2026-06-09 | 4 | LIN SUE-JEAN — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Welgus Howard G. — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Krishnamohan Neha — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Curran Terrie — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Munshi Amit — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Gilbert Halley E — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Leonard Keith R — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Heron Patrick J — Director | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Vairavan Latha — SVP Chief Financial Officer | Sale (S): 435 @ $21.05 | EDGAR |
| 2026-05-13 | 4 | Burnett Patrick — See Remarks | Sale (S): 222 @ $21.05 | EDGAR |
| 2026-05-06 | 4 | Vairavan Latha — SVP Chief Financial Officer | Sale (S): 1,341 @ $23.61 | EDGAR |
| 2026-05-06 | 4 | Watanabe Todd — See Remarks, Director | Sale (S): 3,172 @ $23.61 | EDGAR |
| 2026-05-06 | 4 | Matsuda Masaru — See Remarks | Sale (S): 7,372 @ $23.27 · Sale (S): 884 @ $23.61 | EDGAR |
| 2026-05-06 | 4 | Burnett Patrick — See Remarks | Sale (S): 684 @ $23.61 | EDGAR |
| 2026-05-05 | 4 | Welgus Howard G. — Director | Sale (S): 7,144 @ $22.99 | EDGAR |
| 2026-04-03 | 4 | Welgus Howard G. — Director | Sale (S): 10,000 @ $23.88 | EDGAR |
| 2026-03-04 | 4 | Welgus Howard G. — Director | Sale (S): 10,000 @ $25.65 | EDGAR |
| 2026-03-04 | 4 | Leonard Keith R — Director | Option exercise (M): 27,052 @ $8.63 · Option exercise (M): 12,220 @ $7.51 · Sale (S): 39,272 @ $25.39 · Option exercise (M): 27,052 (derivative) @ $0 · Option exercise (M): 12,220 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Edwards Larry Todd — See Remarks | Grant/award (A): 30,000 @ $0 · Sale (S): 3,584 @ $25.16 · Sale (S): 103 @ $25.91 · Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Watanabe Todd — See Remarks, Director | Grant/award (A): 102,000 @ $0 · Sale (S): 36,281 @ $25.16 · Sale (S): 1,068 @ $25.91 · Grant/award (A): 266,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Matsuda Masaru — See Remarks | Grant/award (A): 37,000 @ $0 · Sale (S): 3,325 @ $27.95 · Sale (S): 6,553 @ $25.16 · Sale (S): 193 @ $25.91 · Sale (S): 1,987 @ $25.70 · Grant/award (A): 97,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Vairavan Latha — SVP Chief Financial Officer | Grant/award (A): 27,000 @ $0 · Sale (S): 2,772 @ $25.16 · Sale (S): 81 @ $25.91 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Burnett Patrick — See Remarks | Grant/award (A): 16,750 @ $0 · Grant/award (A): 30,000 @ $0 · Sale (S): 6,106 @ $25.16 · Sale (S): 181 @ $25.91 · Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Burnett Patrick — See Remarks | Sale (S): 3,675 @ $25.50 · Sale (S): 9,794 @ $25.81 | EDGAR |
Recent 8-K events — Arcutis Biotherapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ARQT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs